» Articles » PMID: 34756511

Heart Transplantation Outcomes in Cardiac Sarcoidosis

Overview
Publisher Elsevier
Date 2021 Nov 10
PMID 34756511
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cardiac sarcoidosis (CS) is a progressive inflammatory cardiomyopathy that can lead to heart failure, arrhythmia, and death. There is limited data on Orthotopic Heart Transplantation (OHT) outcomes in patients with CS. Here we examine outcomes in patients with CS who have undergone OHT at centers throughout the United States from 1987 to 2019.

Methods: This was an analysis of 63,947 adult patients undergoing OHT captured in the United Network for Organ Sharing (UNOS) registry. Patients were characterized as cardiac sarcoidosis (CS) or Non-CS. Baseline characteristics were compared using chi-square and Kruskal-Wallis Tests. Outcomes of interest included primary graft failure, patient survival, treated graft rejection, hospitalization for infection, and post-transplant malignancy.

Results: During the study period 227 patients with CS underwent OHT. Patients with CS were younger, had higher proportion of non-white patients, and received transplants at more urgent statuses. After multivariable modeling there was no difference in survival (HR 0.86, CI 0.59-1.3, p = 0.446) or graft failure (HR 0.849, CI 0.58-1.23, p = 0.394) between patients with CS and Non-CS. Patients with CS had lower odds of rejection (OR 0.558, CI 0.315- 0.985, p = 0.0444). Patients with CS had similar odds of hospitalization for infection and post-transplant malignancy, as Non-CS patients.

Conclusions: Patients with CS and Non-CS had similar post OHT survival, odds of graft failure, hospitalizations for infection, and post-transplant malignancy. Results of this study confirm the role of heart transplantation as a viable option for patients with CS.

Citing Articles

Cardiac Sarcoidosis: A Comprehensive Clinical Review.

Vereckei A, Besenyi Z, Nagy V, Radics B, Vago H, Jenei Z Rev Cardiovasc Med. 2024; 25(2):37.

PMID: 39077350 PMC: 11263157. DOI: 10.31083/j.rcm2502037.


New-Onset Neurosarcoidosis Following Heart Transplant for Cardiac Sarcoidosis.

Deshpande N, Kanelidis A, Nguyen A, Sarswat N, Powers J, Kim G JACC Case Rep. 2024; 29(11):102358.

PMID: 38765201 PMC: 11098943. DOI: 10.1016/j.jaccas.2024.102358.


Cardiac Sarcoidosis-Diagnostic and Therapeutic Challenges.

Korthals D, Bietenbeck M, Konemann H, Doldi F, Ventura D, Schafers M J Clin Med. 2024; 13(6).

PMID: 38541919 PMC: 10970915. DOI: 10.3390/jcm13061694.


Trends and Disparities Around Cardiovascular Mortality in Sarcoidosis: Does Big Data Have the Answers?.

Ahmed R, Sharma R, Chahal C J Am Heart Assoc. 2024; 13(7):e034073.

PMID: 38533935 PMC: 11179766. DOI: 10.1161/JAHA.124.034073.


High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities.

Israel-Biet D, Bernardinello N, Pastre J, Tana C, Spagnolo P Diagnostics (Basel). 2024; 14(4).

PMID: 38396434 PMC: 10887913. DOI: 10.3390/diagnostics14040395.